Metropolitan Life Insurance Company (MetLife)’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-206
| Closed | -$7.64K | – | 2347 |
|
|
2023
Q3 | $7.64K | Hold |
206
| – | – | ﹤0.01% | 2327 |
|
|
2023
Q2 | $8.31K | Hold |
206
| – | – | ﹤0.01% | 2386 |
|
|
2023
Q1 | $15K | Sell |
206
-27
| -12% | -$2.62K | ﹤0.01% | 2014 |
|
|
2022
Q4 | $19.1K | Buy |
233
+104
| +81% | +$10.8K | ﹤0.01% | 2039 |
|
|
2022
Q3 | $12.2K | Sell |
129
-98
| -43% | -$11K | ﹤0.01% | 2246 |
|
|
2022
Q2 | $44.1K | Hold |
227
| – | – | ﹤0.01% | 1582 |
|
|
2022
Q1 | $52.6K | Sell |
227
-677
| -75% | -$216K | ﹤0.01% | 1561 |
|
|
2021
Q4 | $356K | Hold |
904
| – | – | ﹤0.01% | 1636 |
|
|
2021
Q3 | $404K | Hold |
904
| – | – | 0.01% | 1591 |
|
|
2021
Q2 | $351K | Buy |
904
+90
| +11% | +$32.1K | ﹤0.01% | 1748 |
|
|
2021
Q1 | $292K | Sell |
814
-40
| -5% | -$17.7K | ﹤0.01% | 1765 |
|
|
2020
Q4 | $419K | Hold |
854
| – | – | 0.01% | 1473 |
|
|
2020
Q3 | $277K | Buy |
854
+107
| +14% | +$36.4K | ﹤0.01% | 1587 |
|
|
2020
Q2 | $272K | Buy |
747
+136
| +22% | +$34.4K | ﹤0.01% | 1609 |
|
|
2020
Q1 | $130K | Buy |
611
+23
| +4% | +$7.3K | ﹤0.01% | 1870 |
|
|
2019
Q4 | $242K | Sell |
588
-38
| -6% | -$13.1K | ﹤0.01% | 1781 |
|
|
2019
Q3 | $221K | Buy |
626
+92
| +17% | +$34.3K | ﹤0.01% | 1811 |
|
|
2019
Q2 | $268K | Hold |
534
| – | – | ﹤0.01% | 1692 |
|
|
2019
Q1 | $530K | Sell |
534
-16
| -3% | -$14.9K | 0.01% | 1258 |
|
|
2018
Q4 | $478K | Buy |
550
+18
| +3% | +$16.7K | 0.01% | 1214 |
|
|
2018
Q3 | $550K | Hold |
532
| – | – | 0.01% | 1290 |
|
|
2018
Q2 | $489K | Buy |
532
+108
| +25% | +$116K | 0.01% | 1326 |
|
|
2018
Q1 | $413K | Buy |
424
+53
| +14% | +$48.3K | 0.01% | 1398 |
|
|
2017
Q4 | $168K | Sell |
371
-338
| -48% | -$125K | ﹤0.01% | 2010 |
|
|
2017
Q3 | $293K | Hold |
709
| – | – | ﹤0.01% | 2041 |
|
|
2017
Q2 | $248K | Hold |
709
| – | – | ﹤0.01% | 2200 |
|
|
2017
Q1 | $364K | Hold |
709
| – | – | ﹤0.01% | 1871 |
|
|
2016
Q4 | $252K | Hold |
709
| – | – | ﹤0.01% | 2199 |
|
|
2016
Q3 | $379K | Hold |
709
| – | – | ﹤0.01% | 1886 |
|
|
2016
Q2 | $399K | Buy |
709
+231
| +48% | +$111K | ﹤0.01% | 1842 |
|
|
2016
Q1 | $228K | Hold |
478
| – | – | ﹤0.01% | 2092 |
|
|
2015
Q4 | $316K | Hold |
478
| – | – | ﹤0.01% | 1919 |
|
|
2015
Q3 | $376K | Buy |
478
+68
| +17% | +$82.9K | ﹤0.01% | 1824 |
|
|
2015
Q2 | $541K | Buy |
+410
| New | +$470K | ﹤0.01% | 1685 |
|
Other funds holding ATRA
EC
RG
Metropolitan Life Insurance Company (MetLife)'s ATRA Position: Q4 2023 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 206 shares — an estimated $7.64K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in ATRA in Q2 2015 and held it in 34 quarters. The position peaked at $550K in Q3 2018. 89 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 206 Atara Biotherapeutics shares in Q4 2023, an estimated $7.64K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 34 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Atara Biotherapeutics position peaked at $550K in Q3 2018.
- 89 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.